Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study

NEXT STORY
Lateral Flow Assays Market to Reach $13.85 billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis and Forecasts by Meticulous Research®
PREV STORY
BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Intellia Therapeutics Announces First Quarter 2018 Financial Results

author_avatar
NASDAQ Market News

Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results

– Phase 3 VISION Trial Design Finalized for 177Lu-PSMA-617 Following Successful End of Phase ...

author_avatar
NASDAQ Market News

Alladapt Initiates Buildout of New Manufacturing Facility for Production of Novel, Investigational Oral Immunotherapeutic Designed to Address a Broad Range of Food Allergies

author_avatar
NASDAQ Market News